Davipharm: Remarkable Journey To Rise To The Top Of Vietnam Pharmaceutical Market

On its 20-year journey, Davipharm, a member of Adamed Group, has growth from a small local business to one of the leading pharmaceutical companies in Vietnam. With a series of impressive successes and outstanding advances, Davipharm not only shows the development in Vietnam’s pharmaceutical sector but also demonstrates the strength and strategic vision of a member of an international enterprise. All of it standing to its mission and values, continuously responding to the key challenges of modern medicine. 

From humble beginning to become the 8th company  in the RX market. 

Davipharm is one of the most rapidly growing pharmaceutical company, ranking number 8 in the prescription drug market in Vietnam. 

Established in 2004 with the production factory located in Binh Duong, the company got its first WHO-GMP certification in 2006. In 2014, Davipharm had 100 registered products in the portfolio and began its first foreign sales with exporting drugs to the Philippines and Cambodia 

In 2017, Adamed Pharma – Polish pharmaceutical and biotechnology company, became the majority shareholder acquiring 70% of shares in Davipharm.  

Adamed, back then the biggest direct Polish investor in Vietnam, set very ambitious goals for its Vietnamese operations. With US$50 million investment, the company has started the modernization of R&D Centre and manufacturing site in Binh Duong, focusing on the upgrade of technologies and drugs development to provide high-quality-made-in-Vietnam medicines at affordable prices to local patients and to support the Ministry of Health of Vietnam to optimize the spending on drugs. 

Persistent striving in the context of global challenges 

In 2020, amidst the Covid-19 pandemic, Davipharm kept its manufacturing operations running despite the strict lockdown regulations. Volunteers worked hard in a complete isolation in the factory for weeks, to prevent shortages of medicines for Vietnamese patients. In response to our company’s and team’s commitment during this difficult time, the Ministry of Health awarded  Davipharm the Certificate of Merit in the Prevention of COVID-19 Pandemic. 

Photo: Davipharm’s Announcement Ceremony of the certification of the first in Vietnam HP Zone for manufacturing high-potent drugs. 

In 2021, still during the pandemic era, Davipharm successfully certified the first in Vietnam HP Zone for manufacturing high-potent drugs in solid forms, among others high-quality oncology drugs.  
The next year, the company obtained its first EU-GMP certificate, becoming one of several pharmaceutical companies in Vietnam with EU-GMP quality standard. 

2022 was a remarkable year for Davipharm. As a result of a record high post-pandemic production, the company achieved its highest sales result and grew faster than the market. According to IQVIA, by Q1-2023, Davipharm experienced strong growth, with the pharmaceutical market growing by 22% and Davipharm growing by 56%. 

Photo: Malgorzata Adamkiewicz, MD, PhD, President of the Supervisory Board of Adamed Pharma, during her speech to Davipharm’ Team while visiting the manufacturing site in Binh Duong on 27 April 2023.  

In 2023, Adamed confirmed its strong commitment to investing in Vietnam, becoming a 100% shareholder in Davipharm. 

Davipharm currently produces more than 300 drugs in 12 different therapeutic areas with an annual production capacity of up to 1.2 billion units. 

With a team of international experts, managers and employees of more than 450 people with high expertise and extensive experience, Davipharm continuous growing stronger, marking its significance on the pharmaceutical stage in Vietnam.  

Fueled by corporate values, such as flexibility, speed of action, openness, promotion of innovation, quality assurance and operations’ excellence, Davipharm has reached the impressive growth momentum, with revenue in 2023 higher by 47% compared to 2022.  

Expand and develop for the future 

Davipharm continues to build its EU-quality pipeline to make Vietnamese pharmaceutical products more compatible not just nationally, but also on the regional and global pharmaceutical market. 

The company’s new developments based on the technology transfers meet the strict requirements of the highly regulated markets, allowing to produce high-quality medicines not only for Vietnamese patients but also for export to the EU countries. 

But Davipharm’s activities are not limited to products and technologies only. The company is also geared towards human development, societal improvement and environmental concern, which will remain one of key priorities in the coming years. As a socially responsible enterprise, under the brands of Adamed and Davipharm, for many years the company has continuously sponsored the ADAMED SmartUP scientific program to support the local community of Vietnam – Poland High School in Hanoi.  

Davipharm co-organizes a Non-Communicable Diseases Prevention and Early Detection Program “Chăm Sóc Sức Khỏe Việt” in partnership with the Vietnamese Ministry of Health in response to the fact that non-communicable diseases are the leading cause of death in Vietnam.  

Check out the article on VNEconomy newspaper HERE!